Ajinomoto Co., Ltd.

Satoshi Iwayama

Seiji Niwa

Shinichi Fujita

Tomoko Takeda

Hajime Koganei

Akira Takahara

Yukitsugu Ono

Seiji Ohno

Kayo Otani

Takashi Yamamoto

Takashi Tsuji

Masahiko Okunishi

Takaaki Sekiyama

Masako Hagihara

Akiko Okajima

Keiko Moki

Satoshi Hatsuya

Hiroshi Yamamoto

Koji Ohsumi

Tomoyuki Onishi

Naoyuki Fukuchi

Akira Chiba

Sayaka Asari

Koichi Fujita

Misato Noguchi

Itsuya Tanabe

Chiori Ijichi

Yuka Kataba

Naoko Oomuta

Yuko Iida

Chika Mukai

The invention relates to a compound represented by the following general formula (1) or its analogue, which selectively inhibit N-type calcium channels or its analogue, and to a method for treating pain etc. comprising the compound represented by the following general formula (1) or its analogue to a patient in need of such treatment: wherein, A represents CH&#x2550;CH, etc., a, b, c and d represents CH etc., R1, R2, R3, R4, R5 and R6 represents H etc., V&#x2014;W represents C&#x2550;C, etc., n represents 0 to 3, Y1 represents O etc., B represents &#x2014;(CH2)vCHR21 wherein v is 0 to 3, R21 represents H, a lower alkyl group or the like, etc., G represents &#x2014;CO&#x2014;, a covalent bond, etc., m is 0 to 6, R7 and R8 represents H, a lower alkyl group, &#x2014;COR18a, &#x2014;COOR20 wherein R18a and R20 each represents a lower alkyl group or the like, etc.

Diarylalkene derivatives and novel diarylalkane derivatives

The present invention relates to a pharmaceutical composition useful for preventing/treating pain, which comprises combination of gabapentin or pregabalin, or pharmaceutically acceptable salts thereof and N-type calcium channel antagonists or pharmaceutically acceptable salts thereof such as a compound having the following structure. 

Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist

Azole compounds represented by formula I: wherein ring A is isoxazole and the like, R1 is a substituted or unsubstituted aryl group and the like, R2 is a hydrogen atom and the like, and R3 is a substituted or unsubstituted alkyl group and the like, and pharmaceutically acceptable salts thereof inhibit the physiological activity of lysophosphatidic acid (LPA), and are useful as for the prophylaxis or treatment of diseases in which inhibition of the physiological activity of LPA is useful for the prophylaxis or treatment thereof, such as diseases involving the LPA receptor.

Azole compound

Achiral pyrimidine derivatives and pyridine derivatives of the following formulae or analogs thereof have selective N-type calcium channel antagonistic activity and showed analgesic action when they were taken orally. They are useful as therapeutic agents for pains and various diseases associated with the N-type calcium channels. 

Pyridine compounds useful as N-type calcium channel antagonists

Achiral pyrimidine derivatives and pyridine derivatives of the following formulae or analogs thereof have selective N-type calcium channel antagonistic activity and showed analgesic action when they were taken orally. They are useful as therapeutic agents for pains and various diseases associated with the N-type calcium channels 

Pyrimidine compounds useful as N-type calcium channel antagonists

The present invention provides a pharmaceutical agent having a high pharmaceutical potency against varicella-zoster viruses and herpes simplex viruses, compositions containing the same, and methods for treating varicella-zoster viruses using the same.

Cyclopropane derivatives and anti-viral agent containing the same

A cyclopropane derivative of formula (I) ##STR1## wherein B.sup.1 is a purine or pyrimidine residue, R.sup.1 and R.sup.2 are, independently, hydrogen or a protecting group for hydroxyl and each of k, m and n represents, independently, an integer of 1 or 2 is useful for its antiviral effect.

Cyclopropane derivative

Growing community of inventors

Kawasaki, Japan

Satoshi Iwayama